Rapid actions of aldosterone in vascular health and disease--friend or foe?
about
Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".Aldosterone activates transcription factor Nrf2 in kidney cells both in vitro and in vivoAcute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adultsSuperoxide anion and hydrogen peroxide-induced signaling and damage in angiotensin II and aldosterone action.Mineralocorticoid receptors in vascular function and disease.Mineralocorticoid receptor antagonists for heart failure.Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications.Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation.Endothelial dysfunction and vascular disease - a 30th anniversary update.The endothelial mineralocorticoid receptor: mediator of the switch from vascular health to disease.The Link Between Adipose Tissue Renin-Angiotensin-Aldosterone System Signaling and Obesity-Associated Hypertension.Aldosterone induces oxidative stress, oxidative DNA damage and NF-κB-activation in kidney tubule cells.Low doses of fludrocortisone and hydrocortisone, alone or in combination, on vascular responsiveness to phenylephrine in healthy volunteers.Spironolactone inhibits NADPH oxidase-induced oxidative stress and enhances eNOS in human endothelial cells.Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.Aldosterone-induced endothelial dysfunction of rat aorta: role of poly(ADP-ribose) activation.Salt, Aldosterone, and Parathyroid Hormone: What Is the Relevance for Organ Damage?Aldosterone activates the oncogenic signals ERK1/2 and STAT3 via redox-regulated mechanisms.Histamine-dependent prolongation by aldosterone of vasoconstriction in isolated small mesenteric arteries of the mouse.NADPH oxidase-mediated Rac1 GTP activity is necessary for nongenomic actions of the mineralocorticoid receptor in the CA1 region of the rat hippocampus.The selective mineralcorticoid receptor (MR) antagonist eplerenon prevents decompensation of liver cirrhosis.
P2860
Q34121798-8AB45988-54FE-42CB-BC2E-222A699DCAA6Q34431544-818488A5-5C32-4991-8884-0D3225D3645EQ36463640-5402E7E0-DA0B-4F0A-AD1E-86FEDB4365BFQ37792074-931E6032-4A18-422C-8FD0-E1D312CE22F0Q37896953-A7F2A591-DA15-4414-B008-B700E001400CQ37955919-1744695E-DEAF-4E4D-82EE-2BCEECA4D0D0Q38063297-D31E5B23-7EB4-4FA1-83B4-11000CDFDB17Q38109661-295CFE9A-C105-4672-8DA3-CF56FC9372E5Q38680112-B89194F5-86F1-4C9F-9B0D-3FAF8D3DC9DFQ39032836-6E2784BF-5015-4054-9513-86E71D101C26Q39238938-96B27D20-4A1B-42FE-A7BE-255B78753411Q39608480-A27F7817-410E-4AF2-A9A5-ED1C3B81E718Q41774754-237017AD-8849-4DFA-8BBC-8182F19EA26CQ42906092-A7862377-AE2A-42BF-B74C-DA45B7C3E922Q43143859-9EF914F2-9E52-4F46-94BD-8A8C13737397Q43284568-7C1EC656-0F6D-4A35-BC3F-66D6B86E3A32Q44642659-0D540CB1-ABEC-4C9B-9278-C036205D3DE0Q45015877-A5BE8657-DEB3-4EC2-9F30-EB1883136BC2Q50237155-C0CD8DF6-9957-431A-A30B-8766330BBC83Q50981473-1C2E1EC3-5796-475C-ABCE-9DAB9F5ED008Q52570905-775E95D7-0352-4ABB-8AB4-383B9FB7F59C
P2860
Rapid actions of aldosterone in vascular health and disease--friend or foe?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Rapid actions of aldosterone in vascular health and disease--friend or foe?
@ast
Rapid actions of aldosterone in vascular health and disease--friend or foe?
@en
type
label
Rapid actions of aldosterone in vascular health and disease--friend or foe?
@ast
Rapid actions of aldosterone in vascular health and disease--friend or foe?
@en
prefLabel
Rapid actions of aldosterone in vascular health and disease--friend or foe?
@ast
Rapid actions of aldosterone in vascular health and disease--friend or foe?
@en
P2093
P1476
Rapid actions of aldosterone in vascular health and disease--friend or foe?
@en
P2093
Boye L Jensen
Jeppe Schjerning
Lasse E Rasmussen
Pernille B L Hansen
Torben R Uhrenholt
P304
P356
10.1016/J.PHARMTHERA.2005.10.010
P50
P577
2006-01-18T00:00:00Z